Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Saskatchewan

$17,500.00

Identification of new drugs to treat triple negative breast cancer

FY 2018-19

Summary
Breast cancer is the 2nd leading cause of death from cancer in Canadian women, affecting approximately 1 in 8. The four major subtypes of breast cancer are: luminal A, luminal B, HER2+ and triple negative breast cancer (TNBC). TNBCs do not have the clinical characteristics present in the other major subtypes of breast cancer, making them difficult to treat. In addition, breast cancers of this subtype are typically aggressive and highly metastatic (meaning they have the ability to spread throughout the body). Chemotherapy is currently the only treatment option for TNBC. Our lab has been studying a protein, cAMP-responsive element-binding protein 3-like protein 1 (CREB3L1) which inhibits metastasis in breast cancer. Approximately 30% of breast cancers have deficient amounts of CREB3L1 (including ~90% of TNBCs) and these patients usually have a poor prognosis. This project aims to identify new, FDA-approved drugs that effectively target CREB3L1-deficient TNBC. An “Approved Drug Library” of 1818 drugs currently used to treat other diseases will be evaluated for the ability to selectively kill CREB3L1-deficient TNBC cells. This global approach will swiftly and effectively identify the most promising approved drugs to target this specific type of breast cancer. These initial experiments would lay the foundation for pre-clinical evaluations in mice harbouring human TNBCs. Promising results would warrant pursuit of clinical trials to quickly implement the use of these drugs to benefit 90% of the TNBC patients whose cancers are CREB3L1-deficient.
Program
Master's Award: Canada Graduate Scholarships
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406337
Name
Crittenden Riley B
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of new drugs to treat triple negative breast cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer Therapy; Creb3l1; High-Throughput Screening; Tnbc; Triple-Negative Breast Cancer
Abstract
Breast cancer is the 2nd leading cause of death from cancer in Canadian women, affecting approximately 1 in 8. The four major subtypes of breast cancer are: luminal A, luminal B, HER2+ and triple negative breast cancer (TNBC). TNBCs do not have the clinical characteristics present in the other major subtypes of breast cancer, making them difficult to treat. In addition, breast cancers of this subtype are typically aggressive and highly metastatic (meaning they have the ability to spread throughout the body). Chemotherapy is currently the only treatment option for TNBC. Our lab has been studying a protein, cAMP-responsive element-binding protein 3-like protein 1 (CREB3L1) which inhibits metastasis in breast cancer. Approximately 30% of breast cancers have deficient amounts of CREB3L1 (including ~90% of TNBCs) and these patients usually have a poor prognosis. This project aims to identify new, FDA-approved drugs that effectively target CREB3L1-deficient TNBC. An “Approved Drug Library” of 1818 drugs currently used to treat other diseases will be evaluated for the ability to selectively kill CREB3L1-deficient TNBC cells. This global approach will swiftly and effectively identify the most promising approved drugs to target this specific type of breast cancer. These initial experiments would lay the foundation for pre-clinical evaluations in mice harbouring human TNBCs. Promising results would warrant pursuit of clinical trials to quickly implement the use of these drugs to benefit 90% of the TNBC patients whose cancers are CREB3L1-deficient.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Crittenden, Riley B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~